Results 1 to 10 of about 212 (104)
Molecular analysis of the 2012 Bundibugyo virus disease outbreak [PDF]
Cell Reports Medicine, 2021 Bundibugyo virus (BDBV) is one of four ebolaviruses known to cause disease in humans. Bundibugyo virus disease (BVD) outbreaks occurred in 2007-2008 in Bundibugyo District, Uganda, and in 2012 in Isiro, Province Orientale, Democratic Republic of the Congo.
Gustavo Palacios +2 more
exaly +3 more sources
Proportion of Deaths and Clinical Features in Bundibugyo Ebola Virus Infection, Uganda
Emerging Infectious Diseases, 2010 The first known Ebola hemorrhagic fever (EHF) outbreak caused by Bundibugyo Ebola virus occurred in Bundibugyo District, Uganda, in 2007. Fifty-six cases of EHF were laboratory confirmed.
Adam MacNeil +12 more
doaj +5 more sources
Antibodies Cross-Reactive with Bundibugyo Virus in Ferrets Vaccinated with Ebola Virus Vaccine
Emerging Infectious DiseasesBanked serum samples from ferrets previously immunized with the Ebola virus vaccine revealed a prominent but limited humoral immune response that cross-reacted with Bundibugyo virus.
Jordan Wight +2 more
doaj +2 more sources
Bundibugyo virus—perspectives for the current outbreak
npj VirusesIn May 2026 an outbreak of Bundibugyo virus, a close relative of Ebola virus, was detected in the Democratic Republic of the Congo and Uganda. Rapidly increasing case numbers together with the regional circumstances and current lack of licensed ...
Thomas Hoenen
doaj +2 more sources
Alert: how do you respond to Bundibugyo virus disease outbreak?
Lire en français Dear Reader, You know that colleagues in the Democratic Republic of the Congo and Uganda are supporting communities hit by a Bundibugyo virus disease (BVD) outbreak. They are taking real risks to work for health. Here are three things you can do today to support them, each in less than three minutes.
+21 more sources
Bundibugyo Virus Disease: Diagnostics and Medical Countermeasures for a Neglected Ebolavirus
VirusesBundibugyo virus disease, caused by Bundibugyo virus (Orthoebolavirus bundibugyoense), is a severe human Ebola disease with substantial mortality, unresolved reservoir ecology, limited diagnostic implementation, and no licensed vaccines or therapeutics ...
Katharina Kopp
doaj +2 more sources
Ferrets Infected with Bundibugyo Virus or Ebola Virus Recapitulate Important Aspects of Human Filovirus Disease. [PDF]
Journal of Virology, 2016 ABSTRACT Bundibugyo virus (BDBV) is the etiological agent of a severe hemorrhagic fever in humans with a case-fatality rate ranging from 25 to 36%. Despite having been known to the scientific and medical communities for almost 1 decade, there is a dearth of studies on this pathogen due to the lack of a small animal model ...
Gary W K Wong +2 more
exaly +3 more sources
Emerging Microbes and InfectionsBundibugyo virus disease (BVD), caused by Bundibugyo virus (BDBV), is associated with substantial morbidity and mortality, with previous outbreaks reporting case fatality rates of 30%–50%. The ongoing BDBV outbreak in the Democratic Republic of the Congo
Shilpi Jain +5 more
doaj +2 more sources
Social Dynamics of Ebola Virus Disease: A Case of Bundibugyo District, Uganda ()
Health, 2019 Background: Ebola Virus Disease (EVD) presents with a high global mortality and is known to be a highly infectious disease with devastating and gendered effects on the social fabric, yet most of the science has focused on the disease’s biology. However, little has been documented with regard to the gender and social aspects of Ebola Virus Disease (EVD)
James Muleme, Luke Nyakarahuka
exaly +3 more sources
Vesicular Stomatitis Virus-Based Vaccines Protect Nonhuman Primates against Bundibugyo ebolavirus
PLoS Neglected Tropical Diseases, 2013 Ebola virus (EBOV) causes severe and often fatal hemorrhagic fever in humans and nonhuman primates (NHPs). Currently, there are no licensed vaccines or therapeutics for human use. Recombinant vesicular stomatitis virus (rVSV)-based vaccine vectors, which encode an EBOV glycoprotein in place of the VSV glycoprotein, have shown 100% efficacy against ...
Chad E Mire +2 more
exaly +5 more sources